There's no universally superior option here. Seeds reward patience, offer genetic flexibility, and reduce disease risk on entry.
Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225 ...